End-of-day quote
Korea S.E.
23:00:00 13/06/2024 BST
|
5-day change
|
1st Jan Change
|
1,426
KRW
|
-1.45%
|
|
-4.49%
|
+6.10%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
150,623
|
171,701
|
236,254
|
192,780
|
160,723
|
118,039
|
Enterprise Value (EV)
1 |
129,735
|
148,790
|
212,551
|
168,770
|
133,474
|
91,360
|
P/E ratio
|
18.8
x
|
-143
x
|
110
x
|
36
x
|
-22.1
x
|
48.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.16
x
|
9.05
x
|
13.4
x
|
8.44
x
|
5.88
x
|
5.65
x
|
EV / Revenue
|
7.03
x
|
7.84
x
|
12
x
|
7.39
x
|
4.88
x
|
4.37
x
|
EV / EBITDA
|
17.4
x
|
-268
x
|
75.6
x
|
39.9
x
|
18.4
x
|
47.9
x
|
EV / FCF
|
30.5
x
|
33.1
x
|
1,924
x
|
-107
x
|
163
x
|
-45.6
x
|
FCF Yield
|
3.28%
|
3.02%
|
0.05%
|
-0.93%
|
0.61%
|
-2.19%
|
Price to Book
|
2.83
x
|
3.31
x
|
4.41
x
|
3.25
x
|
3.13
x
|
2.17
x
|
Nbr of stocks (in thousands)
|
87,827
|
87,827
|
87,827
|
87,827
|
87,827
|
87,827
|
Reference price
2 |
1,715
|
1,955
|
2,690
|
2,195
|
1,830
|
1,344
|
Announcement Date
|
19/03/19
|
16/03/20
|
15/03/21
|
21/03/22
|
21/03/23
|
20/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
18,450
|
18,980
|
17,651
|
22,849
|
27,337
|
20,887
|
EBITDA
1 |
7,469
|
-555.7
|
2,811
|
4,232
|
7,259
|
1,908
|
EBIT
1 |
7,334
|
-822.3
|
2,584
|
3,953
|
6,908
|
1,462
|
Operating Margin
|
39.75%
|
-4.33%
|
14.64%
|
17.3%
|
25.27%
|
7%
|
Earnings before Tax (EBT)
1 |
7,982
|
-1,201
|
2,074
|
3,704
|
-6,281
|
2,291
|
Net income
1 |
7,996
|
-1,201
|
2,140
|
5,360
|
-7,282
|
2,436
|
Net margin
|
43.34%
|
-6.33%
|
12.12%
|
23.46%
|
-26.64%
|
11.66%
|
EPS
2 |
91.05
|
-13.67
|
24.37
|
61.03
|
-82.91
|
27.74
|
Free Cash Flow
1 |
4,250
|
4,495
|
110.5
|
-1,572
|
819.1
|
-2,002
|
FCF margin
|
23.04%
|
23.68%
|
0.63%
|
-6.88%
|
3%
|
-9.59%
|
FCF Conversion (EBITDA)
|
56.9%
|
-
|
3.93%
|
-
|
11.28%
|
-
|
FCF Conversion (Net income)
|
53.15%
|
-
|
5.16%
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/19
|
16/03/20
|
15/03/21
|
21/03/22
|
21/03/23
|
20/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
20,888
|
22,912
|
23,703
|
24,010
|
27,249
|
26,680
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
4,250
|
4,495
|
110
|
-1,572
|
819
|
-2,002
|
ROE (net income / shareholders' equity)
|
16.3%
|
-2.29%
|
4.06%
|
9.49%
|
-13.1%
|
4.6%
|
ROA (Net income/ Total Assets)
|
8.63%
|
-0.9%
|
2.74%
|
3.94%
|
7.15%
|
1.61%
|
Assets
1 |
92,656
|
133,933
|
78,121
|
135,978
|
-101,883
|
150,968
|
Book Value Per Share
2 |
606.0
|
590.0
|
610.0
|
676.0
|
585.0
|
620.0
|
Cash Flow per Share
2 |
133.0
|
92.70
|
97.70
|
101.0
|
145.0
|
137.0
|
Capex
1 |
231
|
100
|
309
|
516
|
490
|
156
|
Capex / Sales
|
1.25%
|
0.53%
|
1.75%
|
2.26%
|
1.79%
|
0.75%
|
Announcement Date
|
19/03/19
|
16/03/20
|
15/03/21
|
21/03/22
|
21/03/23
|
20/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +6.10% | 90.5M | | +50.70% | 791B | | +41.96% | 630B | | -7.15% | 350B | | +18.77% | 328B | | +8.79% | 298B | | +18.02% | 246B | | +1.27% | 225B | | +11.95% | 218B | | +3.68% | 160B |
Other Pharmaceuticals
|